Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 9 | 2017 | 630 | 1.570 |
Why?
|
| Diagnostic Imaging | 9 | 2015 | 476 | 1.210 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2015 | 2633 | 0.960 |
Why?
|
| Prostate | 6 | 2021 | 391 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 3429 | 0.870 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2017 | 432 | 0.860 |
Why?
|
| Embolization, Therapeutic | 4 | 2021 | 255 | 0.850 |
Why?
|
| Prostatic Neoplasms | 9 | 2022 | 1763 | 0.770 |
Why?
|
| Prostatic Hyperplasia | 2 | 2019 | 91 | 0.740 |
Why?
|
| Radiology | 5 | 2017 | 197 | 0.670 |
Why?
|
| Testicular Neoplasms | 2 | 2023 | 113 | 0.650 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 1349 | 0.610 |
Why?
|
| Ultrasonography | 8 | 2023 | 703 | 0.520 |
Why?
|
| Spermatic Cord | 1 | 2014 | 5 | 0.500 |
Why?
|
| Epididymitis | 1 | 2014 | 5 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 6 | 2015 | 1034 | 0.490 |
Why?
|
| Radiographic Image Enhancement | 2 | 2014 | 463 | 0.480 |
Why?
|
| Contrast Media | 7 | 2015 | 1084 | 0.470 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2011 | 82 | 0.460 |
Why?
|
| Scrotum | 4 | 2023 | 17 | 0.460 |
Why?
|
| Hemangioma | 2 | 2011 | 64 | 0.450 |
Why?
|
| Chyle | 1 | 2012 | 5 | 0.420 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2012 | 9 | 0.420 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2012 | 6 | 0.420 |
Why?
|
| Surgical Sponges | 1 | 2011 | 3 | 0.410 |
Why?
|
| Tuberculosis, Endocrine | 1 | 2011 | 1 | 0.410 |
Why?
|
| Adrenal Gland Diseases | 1 | 2011 | 14 | 0.410 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2011 | 10 | 0.400 |
Why?
|
| Orchitis | 1 | 2011 | 10 | 0.400 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 176 | 0.400 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2011 | 11 | 0.400 |
Why?
|
| Granuloma | 1 | 2011 | 65 | 0.390 |
Why?
|
| Medical Oncology | 2 | 2013 | 375 | 0.380 |
Why?
|
| Ileum | 1 | 2011 | 162 | 0.380 |
Why?
|
| Foreign Bodies | 1 | 2011 | 65 | 0.380 |
Why?
|
| Kidney | 3 | 2015 | 1145 | 0.380 |
Why?
|
| Urinary Bladder | 1 | 2012 | 246 | 0.350 |
Why?
|
| Diagnosis, Differential | 11 | 2023 | 1587 | 0.340 |
Why?
|
| Humans | 43 | 2023 | 88365 | 0.340 |
Why?
|
| Middle Aged | 17 | 2019 | 25612 | 0.330 |
Why?
|
| Carcinoma | 1 | 2011 | 441 | 0.300 |
Why?
|
| Nephrectomy | 4 | 2015 | 293 | 0.300 |
Why?
|
| Testis | 2 | 2011 | 152 | 0.290 |
Why?
|
| Male | 26 | 2023 | 41896 | 0.290 |
Why?
|
| Angiomyolipoma | 2 | 2017 | 17 | 0.280 |
Why?
|
| Testicular Diseases | 2 | 2018 | 8 | 0.260 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2015 | 21 | 0.250 |
Why?
|
| Image-Guided Biopsy | 3 | 2022 | 66 | 0.250 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 849 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 3 | 2022 | 358 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 6704 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 2532 | 0.200 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1978 | 0.200 |
Why?
|
| Arteries | 2 | 2019 | 180 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3655 | 0.190 |
Why?
|
| Aged | 10 | 2020 | 18878 | 0.190 |
Why?
|
| Female | 13 | 2015 | 45621 | 0.180 |
Why?
|
| Brachytherapy | 1 | 2021 | 121 | 0.180 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 91 | 0.180 |
Why?
|
| Radiology Information Systems | 1 | 2020 | 77 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2332 | 0.170 |
Why?
|
| Endosonography | 1 | 2019 | 98 | 0.160 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2017 | 30 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2012 | 392 | 0.150 |
Why?
|
| Physician Assistants | 1 | 2017 | 22 | 0.140 |
Why?
|
| Radiologists | 1 | 2017 | 45 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2019 | 4263 | 0.130 |
Why?
|
| Radiography | 3 | 2012 | 810 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 176 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2743 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2020 | 8852 | 0.110 |
Why?
|
| Flank Pain | 1 | 2012 | 5 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 384 | 0.110 |
Why?
|
| Observer Variation | 1 | 2014 | 607 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 366 | 0.110 |
Why?
|
| Urinary Calculi | 1 | 2012 | 46 | 0.110 |
Why?
|
| Mass Screening | 2 | 2017 | 631 | 0.100 |
Why?
|
| Curriculum | 1 | 2017 | 565 | 0.100 |
Why?
|
| Cystitis | 1 | 2012 | 14 | 0.100 |
Why?
|
| Acute Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2019 | 2833 | 0.100 |
Why?
|
| United States | 6 | 2017 | 6867 | 0.100 |
Why?
|
| Pelvis | 1 | 2012 | 94 | 0.100 |
Why?
|
| Urinary Diversion | 1 | 2011 | 42 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 77 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2012 | 295 | 0.100 |
Why?
|
| Paraganglioma | 1 | 2011 | 16 | 0.100 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 67 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2011 | 163 | 0.100 |
Why?
|
| Lymphatic Vessels | 1 | 2012 | 69 | 0.100 |
Why?
|
| Rituximab | 1 | 2011 | 119 | 0.100 |
Why?
|
| Pelvic Pain | 1 | 2012 | 84 | 0.090 |
Why?
|
| Young Adult | 2 | 2014 | 6179 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 223 | 0.090 |
Why?
|
| Prostatic Diseases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Lipids | 1 | 2012 | 269 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 573 | 0.090 |
Why?
|
| Urination Disorders | 1 | 2010 | 50 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 307 | 0.090 |
Why?
|
| Lipoma | 1 | 2010 | 27 | 0.090 |
Why?
|
| Biopsy | 3 | 2022 | 1187 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 335 | 0.090 |
Why?
|
| Kidney Calices | 1 | 2008 | 5 | 0.080 |
Why?
|
| Kidney Diseases | 2 | 2008 | 318 | 0.080 |
Why?
|
| Adult | 8 | 2017 | 26266 | 0.080 |
Why?
|
| Lithium | 1 | 2008 | 58 | 0.080 |
Why?
|
| Patient Selection | 1 | 2012 | 689 | 0.080 |
Why?
|
| Kidney Medulla | 1 | 2008 | 80 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1704 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 769 | 0.080 |
Why?
|
| Cysts | 1 | 2008 | 106 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2010 | 303 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2019 | 8136 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2005 | 261 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2020 | 561 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 773 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2002 | 38 | 0.050 |
Why?
|
| Adolescent | 1 | 2014 | 9138 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 58 | 0.050 |
Why?
|
| Dogs | 1 | 2021 | 703 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2402 | 0.040 |
Why?
|
| Pain | 1 | 2002 | 399 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2003 | 404 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2010 | 2019 | 0.040 |
Why?
|
| Hemospermia | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dysuria | 1 | 2018 | 8 | 0.040 |
Why?
|
| Urinary Retention | 1 | 2018 | 42 | 0.040 |
Why?
|
| Hematuria | 1 | 2018 | 51 | 0.040 |
Why?
|
| Rectum | 1 | 2019 | 148 | 0.040 |
Why?
|
| Urodynamics | 1 | 2018 | 122 | 0.040 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2018 | 63 | 0.040 |
Why?
|
| Angiography | 1 | 2018 | 208 | 0.040 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2018 | 65 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 1226 | 0.040 |
Why?
|
| Prostatectomy | 1 | 2020 | 476 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1688 | 0.030 |
Why?
|
| False Positive Reactions | 2 | 2005 | 222 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 185 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 98 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1488 | 0.030 |
Why?
|
| Catheter Ablation | 1 | 2015 | 251 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2012 | 39 | 0.030 |
Why?
|
| Cognition | 1 | 2016 | 577 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 661 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1646 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 307 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 105 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 390 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 901 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2005 | 155 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 681 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 3746 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2005 | 172 | 0.020 |
Why?
|
| Safety | 1 | 2005 | 151 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 27134 | 0.010 |
Why?
|